Targeting Glucose Reliance of Lung Squamous Cell Carcinoma
Abstract
The overall goal of this proposal is to evaluate elevated blood glucose levels as a metabolic biomarker with prognostic feasibilities for lung squamous cell carcinoma (LSCC) patients (Aim 1) and to investigate whether dietary (Aim 2) and pharmacological (Aim 3) glucose restriction can suppress tumor progression of LSCC. Toward this end, we successfully demonstrated that high blood glucose levels are strongly associated with poor overall survival in LSCC patients. We also performed comprehensive in vivo tumor xenograft experiments, in which LSCC tumor bearing mice were fed with ketogenicdiet (KD, dietary glucose restriction) or treated with small molecule inhibitor of sodium-glucose co-transporter 2 (SGLT2,pharmacological glucose restriction). We have shown that KD or SGLT 2 inhibition specifically inhibited tumor growth of LSCC but not lung adenocarcinoma (LADC) supporting our central hypothesis that targeting glucose reliance of LSCC can be a novel targeted therapeutic strategy for LSCC patients. These results have been presented at the Keystone Symposia Tumor Metabolism (Colorado, USA, Feb 2428, 2019) and recently published at Cell Reports (Hsieh et. al. 2019;28(7):1860-78.e9).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1118643
Entities
People
- Tae Kim
Organizations
- University of Texas at Dallas